Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Germany May Make Drug Prices Confidential In AMNOG Update

Executive Summary

Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.


Related Content

No Thaw In Sight: German Bill Extends Price Freeze To 2022
European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate
What will become of the German antidiabetics market?
Honing market access tactics given German drug assessment/price trends
Biogen Idec’s Tecfidera Facing Tough Pricing Talks In Germany


Related Companies